Valuation: Edesa Biotech, Inc.

Market Cap 54.18M 47.54M 44.9M 40.92M 76.6M 5.19B 77.15M 537M 208M 2.65B 203M 199M 8.53B P/E 2026 *
-2.02x
P/E 2027 * -1.94x
Enterprise Value 54.18M 47.54M 44.9M 40.92M 76.6M 5.19B 77.15M 537M 208M 2.65B 203M 199M 8.53B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.5%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week-3.14%
Current month-15.31%
1 month-12.83%
3 months-51.04%
6 months-31.10%
Current year+182.39%
1 week 3.9
Extreme 3.9
4.2
1 month 3.84
Extreme 3.8395
5.1
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
62.65
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 2015-07-31
Director of Finance/CFO 57 2025-04-30
President 48 2019-06-06
Director TitleAgeSince
Chairman 50 2019-06-06
Director/Board Member 55 2019-06-06
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Founder

5,714 0.0593%
8/3/26 Free

Founder

5,324 0.0553%
7/2/26 Free

Founder

3,378 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-3.14%+61.04%-27.02% 54.18M
-3.30%+1.50%+57.79%+85.24% 72.26B
+1.25%-3.01%+37.83%+84.34% 60.24B
+0.09%+0.38%+34.34%+20.63% 27.73B
-3.06%-1.81%-14.01%+354.94% 25.73B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+23.72%-9.50% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%-0.34%+48.98%+162.10% 14.41B
-3.00%-8.23%-8.23%+483.08% 14.23B
Average -0.95%+0.08%+39.21%+147.25% 27.52B
Weighted average by Cap. -1.09%+0.31%+37.81%+126.14%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.38M -14.52M -13.24M -24.78M -1.68B -24.95M -174M -67.32M -858M -65.8M -64.37M -2.76B -23.88M -20.95M -19.79M -18.03M -33.76M -2.29B -34M -237M -91.72M -1.17B -89.65M -87.71M -3.76B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
26-09-25 US$4.010 -0.50% 16,764
26-09-24 US$4.030 +1.51% 29,567
26-09-23 US$3.970 -2.46% 25,466
26-09-22 US$4.070 -0.97% 26,115
26-09-21 US$4.110 -0.72% 42,033
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.010USD
Average target price
16.33USD
Spread / Average Target
+307.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock